First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
Antineoplastic Agents, Immunological
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
/ diagnosis
Clinical Trials as Topic
Humans
Immunomodulation
/ drug effects
Lung Neoplasms
/ diagnosis
Molecular Targeted Therapy
Prognosis
Treatment Outcome
Advanced
CTLA-4
Checkpoint inhibitors
Chemotherapy
First-line
Immuno-Oncology
Immunotherapy
NSCLC
Non-Small-Cell Lung Cancer
PD-1
PD-L1
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
17
03
2019
revised:
31
05
2019
accepted:
06
06
2019
entrez:
20
7
2019
pubmed:
20
7
2019
medline:
23
6
2020
Statut:
ppublish
Résumé
The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone. After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations.
Identifiants
pubmed: 31319988
pii: S0169-5002(19)30500-8
doi: 10.1016/j.lungcan.2019.06.007
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-253Informations de copyright
Crown Copyright © 2019. Published by Elsevier B.V. All rights reserved.